Significant associations of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer

Journal of Clinical Oncology

Volumn 27, Issue 10, 2009, Pages 1592-1599

  Dong, Xiaoqun ^a   Jiao, Li ^a   Li, Yanan ^a   Evans, Douglas B ^a   Wang, Huamin ^a   Hess, Kenneth R ^a   Abbruzzese, James L ^a   Li, Donghui ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; EXONUCLEASE; EXONUCLEASE 1; GEMCITABINE; POSTMEIOTIC SEGREGATION INCREASED 1 PROTEIN; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH3; PROTEIN MSH6; THREE PRIME REPAIR EXONUCLEASE 1; TUMOR PROTEIN; TUMOR PROTEIN 73; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MISMATCH REPAIR; ONCOGENE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PREDICTOR VARIABLE; PREOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME;

ADENOCARCINOMA; AGED; CLINICAL TRIALS, PHASE II AS TOPIC; COMBINED MODALITY THERAPY; DNA MISMATCH REPAIR; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PANCREATIC NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 63749130819     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.20.1111     Document Type: Article

References (39)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics 2007. CA Cancer J Clin 57:43-66, 2007
2. Relling MV, Dervieux T: Pharmacogenetics and cancer therapy. Nat Rev Cancer 1:99-108, 2001
3. Shastry BS: Genetic diversity and new therapeutic concepts. J Hum Genet 50:321-328, 2005
4. Crul M, van Waardenburg RC, Bocxe S, et al: DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcit- abine and cisplatin. Biochem Pharmacol 65:275-282, 2003
5. Baker CH, Banzon J, Bollinger JM, et al: 2'-Deoxy-2'-methylenecytidine and 2'-deoxy-2',2'- difluorocytidine 5'-diphosphates: Potent mechanism- based inhibitors of ribonucleotide reductase. J Med Chem 34:1879-1884, 1991
6. Huang P, Chubb S, Hertel LW, et al: Action of 2',2'-diflourodeoxycytidine on DNA synthesis. Cancer Res 51:6110-6117, 1991
7. Robinson BW, Im MM, Ljungman M, et al: Enhanced radiosensitization with gemcitabine in mismatch repair-deficient HCT116 cells. Cancer Res 63:6935-6941, 2003
8. Kondo E, Furukawa T, Yoshinaga K, et al: Not hMSH2 but hMLH1 is frequently silenced by hyper- methylation in endometrial cancer but rarely silenced in pancreatic cancer with microsatellite instability. Int J Oncol 17:535-541, 2000
9. Goggins M, Kern SE, Offerhaus JA, et al: Progress in cancer genetics: Lessons from pancreatic cancer. Ann Oncol 10:4-8, 1999 (suppl 4)
10. Maple JT, Smyrk TC, Boardman LA, et al: Defective DNA mismatch repair in long-term (> or =3 years) survivors with pancreatic cancer. Pancre-atology 5:220-227, 2005
11. Li D, Frazier M, Evans DB, et al: Single nucle-otide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer. J Clin Oncol 24:1720-1728, 2006
12. Doherty KM, Sharma S, Uzdilla LA, et al: RECQ1 helicase interacts with human mismatch repair factors that regulate genetic recombination. J Biol Chem 280:28085-28094, 2005
13. Varadhachary GR, Wolff RA, Crane CH, et al: Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26:3487-3495, 2008
14. Evans DB, Varadhachary GR, Crane CH, et al: Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26:3496-3502, 2008
15. Wacholder S, Chanock S, Garcia-Closas M, et al: Assessing the probability that a positive report is false: An approach for molecular epidemiology studies. J Natl Cancer Inst 96:434-442, 2004
16. Morgan MA, Parsels LA, Parsels JD, Mesi-wala AK, Maybaum J, Lawrence TS: Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine. Cancer Res 65:68356842, 2005
17. Karnitz LM, Flatten KS, Wagner JM, et al: Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival. Mol Pharmacol 68:1636-1644, 2005
18. Matthews DJ, Yakes FM, Chen J, et al: Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo. Cell Cycle 6:104-110, 2007
19. Okazaki T, Jiao L, Chang P, et al: Single nucleotide polymorphisms of DNA damage response genes are associated with overall survival in patients with pancreatic cancer. Clin Cancer Res 14:2042-2048, 2008
20. Acharya S, Wilson T, Gradia S, et al: HMSH2 forms specific mispair-binding complexes with hMSH3 and hMSH6. Proc Natl Acad SciUSA 93:13629-13634, 1996
21. Wang Y, Qin J: MSH2 and ATR form a signaling module and regulate two branches of the damage response to DNA methylation. Proc Natl Acad SciUSA 100:15387-15392, 2003
22. Yang YG, Lindahl T, Barnes DE: Trex1 exonu- clease degrades ssDNA to prevent chronic checkpoint activation and autoimmune disease. Cell 131: 873-886, 2007
23. Marabese M, Vikhanskaya F, Broggini M: P73: A chiaroscuro gene in cancer. Eur J Cancer 43:13611372, 2007
24. Irwin MS, Kondo K, Marin MC, et al: Chemo-sensitivity linked to p73 function. Cancer Cell 3:403410, 2003
25. Shimodaira H, Yoshioka-Yamashita A, Kolod-ner RD, et al: Interaction of mismatch repair protein PMS2 and the p53-related transcription factor p73 in apoptosis response to cisplatin. Proc Natl Acad Sci USA 100:2420-2425, 2003
26. Tishkoff DX, Boerger AL, Bertrand P, et al: Identification and characterization of Saccharomy- ces cerevisiae EXO1, a gene encoding an exonu- clease that interacts with MSH2. Proc Natl Acad Sci U S A 94:7487-7492, 1997
27. Schmutte C, Sadoff MM, Shim K-S, et al: The interaction of DNA mismatch repair proteins with human exonuclease I. J Biol Chem 276:3301133018, 2001
28. Genschel J, Bazemore LR, Modrich P: Human exonuclease I is required for 5' and 3' mismatch repair. J Biol Chem 277:13302-13311, 2002
29. Gonzalez S, Prives C, Cordon-Cardo C: P73alpha regulation by Chk1 in response to DNA damage. Mol Cell Biol 23:8161-8171, 2003
30. El-Shemerly M, Hess D, Pyakurel AK, Moselhy S, Ferrari S: ATR-dependent pathways control hEXO1 stability in response to stalled forks. Nucleic Acids Res 36:511-519, 2008
31. Mazumder B, Seshadri V, Fox PL: Transla- tional control by the 3'-UTR: The ends specify the means. Trends Biochem Sci 28:91-98, 2003
32. Pickering BM, Willis AE: The implications of structured 5' untranslated regions on translation and disease. Semin Cell Dev Biol 16:39-47, 2005
33. Jiricny J: The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol 7:335-346, 2006
34. Hitchins MP, Wong JJ, Suthers G, et al: Inheritance of a cancer-associated MLH1 germ-line epimutation. N Engl J Med 356:697-705, 2007
35. Kazama Y, Watanabe T, Kanazawa T, et al: Poorly differentiated colorectal adenocarcinomas show higher rates of microsatellite instability and promoter methylation of p16 and hMLH1: A study matched for T classification and tumor location. J Surg Oncol 97:278-283, 2008
36. Johannsdottir JT, Bergthorsson JT, Gretars- dottir S, et al: Replication error in colorectal carcinoma: Association with loss of heterozygosity at mismatch repair loci and clinicopathological variables. Anticancer Res 19:1821-1826, 1999
37. Colebatch A, Hitchins M, Williams R, et al. The role of MYH and microsatellite instability in the development of sporadic colorectal cancer. Br J Cancer 95:1239-1243, 2006
38. Pors K, Patterson LH: DNA mismatch repair deficiency, resistance to cancer chemotherapy and the development of hypersensitive agents. Curr Top Med Chem 5:1133-1149, 2005
39. Fedier A, Fink D: Mutations in DNA mismatch repair genes: Implications for DNA damage signalling and drug sensitivity. Int J Oncol 24:1039-1047, 2004